SOC

Surgery on Children Journal aims to publish issues related to Pediatric Surgery, Pediatric Neurosurgery, Pediatric Plastic Surgery, Pediatric Cardiovascular Surgery, Pediatric Orthopedic Surgery, Pediatric Vascular Surgery, Pediatric Gynecology and Obstetrics, Pediatric Ear Nose Throat, Ophthalmology, Pediatric Anesthesiology and Reanimation, Pediatric Urology, Pediatric Surgical Intensive Care Clinic, and other clinical surgery fields on children of the highest scientific and clinical value at an international level and accepts articles on these topics.

EndNote Style
Index
Original Article
The effect of combined use of oxybutynin and fulguration in children with PUV: experience in a tertiary center in Bangladesh
Aims: Posterior Urethral Valve (PUV) is a common congenital urethral obstruction leading to significant morbidity. Despite successful fulguration of posterior urethral valve, the bladder dysfunction persists in most of the cases. Oxybutynin, an anticholinergic drug is commonly used to manage this bladder dysfunction. This study aimed to assess the impact of oxybutynin on bladder and urinary tract function in children with valve fulguration.
Methods: A retrospective observational study was conducted on 41 children who underwent PUV fulguration at a tertiary care center in Bangladesh between 2020 and 2023. All subjects received oxybutynin for at least 6 months post-fulguration. Bladder wall morphology, hydronephrosis, vesicoureteral reflux (VUR), and post void residues (PVR) were assessed. Side effects of oxybutynin were also documented.
Results: All patients had bilateral hydroureteronephrosis (HUN), except one, who was with unilateral HUN during primary diagnosis. Complete resolution of bilateral HUN was seen in Renal USG 14 patients at 6 months post fulguration. Correction of VUR documented in 13 units out of 32 units. Mean serum creatinine decreased to 0.52 ± 0.22from 0.73 ± 0.52 within 6 months of fulguration. Four patients exhibited significant PVR, leading to clean intermittent catheterization (CIC) initiation.
Conclusion: Combined with PUV fulguration and oxybutynin therapy appears to be effective in improving bladder function. Further prospective studies incorporating urodynamic evaluations are warranted to validate these findings.


1. Bain A, Lavoie C, Rodriguez-Lopez S, Kiddoo D. Renal outcomes of children born with posterior urethral valves at a tertiary center: a 15-year retrospective review. Can Urol Assoc J. 2023;17(4):111-116. doi:10.5489/cuaj.8102
2. Hyman M, Groutz A, Blaivas J. Detrusitor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001; 166(2):550-552.
3. Planta D, Gerwinn T, Salemi S, Horst M. Neurogenic lower urinary tract dysfunction in spinal dysraphism: morphological and molecular evidence in children. Int J Mol Sci. 2023;24(4):3692. doi:10.3390/ijms24043692
4. Bingham G, Leslie SW, Rentea RM. Posterior urethral valves. [Updated 2024 May 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK560881/ 2024.
5. Peters CA, Bolkier M, Bauer SB, et al. The urodynamic consequences of posterior urethral valves. J Urol. 1990;114(1):122-126.
6. McCrery RJ, Appell RA. Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag. 2006;2(1):19-24.
7. Sarhan OM, Wadie B, Al-Kawai F, Dawaba M. Bladder function in children with posterior urethral valves: impact of antenatal versus postnatal diagnosis. Int Braz J Urol. 2022;48(1):78-86. doi:10.1590/S1677-5538.IBJU. 2021.0046
8. Casey JT, Hagerty JA, Maizels M, et al. Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol. 2012;188(4 Suppl):1516-1520.
9. Norris JJ, Raj JP, Thomas TT, Maleperambil TT, Shubha AM. Effects of oxybutynin in children with posterior urethral valves post fulguration: report in a select cohort of children. J Family Med Prim Care. 2021;10(10): 3706-3711.
10. Ezel Çelakil M, Ekinci Z, BozkayaYücel B, Mutlu N, Günlemez A, Bek K. Outcome of posterior urethral valve in 64 children. Single center experience of 22 years. Minerva Urol Nefrol. 2019;71(6):651-656.
11. Petersen KL, Moore DP, Kala UK. Posterior urethral valves in South African boys: outcomes and challenges. S Afr Med J. 2018;108(8):667-670.
12. Kim YH, Horowitz M, Combs AJ, Nitti VW, Borer J, Glassberg KI. Management of posterior urethral valves on the basis of urodynamic findings. J Urol. 1997;158(3 Pt 2):1011-1016.
13. Greenland JE, Brading AF. The effects of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165(1):245-248.
14. Wani SA, Babu N, Faheem M, Jadhav V, Ramesh S, Deepak J. Early use of bladder relaxant (oxybutynin) in posterior urethral valve patients. Is it justified? Med Sur Urol. 2019;8:222. doi: 10.24105/2168-9857.8.222
15. Misseri R, Combs AJ, Horowitz M, Donohoe JM, Glassberg KI. Myogenic failure in posterior urethral valve disease: real or imagined? J Urol. 2002; 168(4 Pt 2):1844-1848.
16. Sharma S, Joshi M, Gupta DK, et al. Consensus on the management of posterior urethral valves from antenatal period to puberty. J Indian Assoc Pediatr Surg. 2019;24(1):4-14.
17. Abdelhalim A, El-Hefnawy AS, Dawaba ME, Bazeed MA, Hafez AT. Effect of early oxybutynin treatment on posterior urethral valve outcomes in infants: a randomized controlled trial. Journal of Urology [Internet]. 2020 Apr 1 [cited 2024 Oct 17];203(4):826-31. Available from: https://doi.org/10.1097/JU.0000000000000691
18. Lieberman JA. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):20-23.
Volume 2, Issue 1, 2025
Page : 1-4
_Footer